Research progress and clinical translation challenges in the use of oncolytic bacteria for cancer therapy

Area of Science:

• Oncology
• Microbiology
• Immunotherapy

Background:

• Oncolytic bacteria selectively infect and colonize tumor tissues, sparing normal cells.
• These bacteria exert anti-tumor effects by activating host immune responses, leading to tumor cell killing.
• Oncolytic bacteria are classified into direct, indirect, and prophylactic types based on their mechanisms.

Purpose of the Study:

• To review bacterial species used in cancer therapy.
• To identify key obstacles hindering the clinical translation of oncolytic bacteria.
• To provide a foundation for developing improved oncolytic bacterial strategies.

Main Methods:

• Systematic review of oncolytic bacteria in cancer therapy.
• Analysis of challenges in clinical translation, including immunogenicity and distribution.
• Examination of bacterial species and their anti-tumor mechanisms.

Main Results:

• Oncolytic bacteria show promise by activating anti-tumor immunity.
• Suboptimal immunogenicity and uneven in vivo distribution are major clinical hurdles.
• Current strategies face limitations in efficacy and broad application.

Conclusions:

• Further research is needed to overcome challenges in oncolytic bacterial therapy.
• Developing safer and more effective oncolytic bacterial strategies is crucial for clinical success.
• Addressing immunogenicity and distribution issues will enhance therapeutic potential.